Sentinel lymph node biopsy status is not the most powerful predictor of prognosis in cutaneous melanoma
- 24 October 2017
- journal article
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 58 (4), 256-258
- https://doi.org/10.1111/ajd.12732
Abstract
Sentinel lymph node (SLN) status has been advocated in several recently published articles as the single most valuable prognostic marker for melanoma, and of greater prognostic importance than more established parameters such as Breslow thickness. A careful examination of the evidence for these claims, however, indicates that they are not substantiated by the available data, are somewhat misleading and suggest misinterpretation of the statistical analysis of the papers to which they refer. We will examine the basis for these claims and show why they are invalid.This publication has 13 references indexed in Scilit:
- Multicenter Selective Lymphadenectomy Trial-I confirms the central role of sentinel node biopsy in contemporary melanoma managementBritish Journal of Dermatology, 2015
- Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in MelanomaThe New England Journal of Medicine, 2014
- Cox proportional hazards regressionBMJ, 2013
- Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous MelanomaJournal of Clinical Oncology, 2012
- Melanoma sentinel node biopsy and prediction models for relapse and overall survivalBritish Journal of Cancer, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Lessons learned from the Sunbelt Melanoma TrialJournal of Surgical Oncology, 2004
- Metastatic pathways and time courses in the orderly progression of cutaneous melanomaBritish Journal of Dermatology, 2002
- A Conversation with Sir David CoxStatistical Science, 1994
- Measurement of Progress Against CancerJNCI Journal of the National Cancer Institute, 1990